Advertisement

Picture Eurasanté BioFIT 2017 Strasbourg France November 600x60px
Document › Details

Merus N.V.. (8/10/16). "Press Release: Merus to Present at the 2016 Wedbush PacGrow Healthcare Conference". Utrecht.

Organisations Organisation Merus N.V. (Nasdaq: MRUS)
  Group Merus (Group)
  Organisation 2 Wedbush PacGrow
  Group Wedbush (Group)
Products Product Wedbush PacGrow Healthcare Conference 2016 New York
  Product 2 Biclonics™ antibody
Index terms Index term Merus–Wedbush: investor conference, 201608 supply service Merus presents at Wedbush PacGrow Healthcare Conference in NYC
  Index term 2 Merus–Argot Partners: public relations, 201605 service existent IR by Argot Partners
Persons Person Margetson, Shelley (Merus 201611– COO before CFO)
  Person 2 Minarovich, Kimberly (Argot Partners 201608)
     


Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that the Company will present at the 2016 Wedbush PacGrow Healthcare Conference on Wednesday, August 17 at 2:30 PM ET at the Le Parker Meridien in New York City.

A live webcast of the presentation will be available on the Investor page of the Company's website. An archived presentation will be available for 90 days.


About Merus N.V.

Merus is a clinical-stage immuno-oncology company developing innovative full length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics® are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have several of the same features of conventional monoclonal antibodies, such as long half-life and low immunogenicity. Merus' lead bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial in Europe as a potential treatment for HER2-expressing solid tumors. Merus' second bispecific antibody candidate, MCLA-117, is being developed as a potential treatment for acute myeloid leukemia. The Company also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors, and Biclonics® designed to bind to various combinations of immunomodulatory molecules, including PD-1 and PD-L1.


Merus N.V.
Shelley Margetson –
s.margetson@merus.nl
+31 (0)30 253 8800

Argot Partners
Kimberly Minarovich –
kimberly@argotpartners.com
1-212-600-1902

Merus N.V.

   
Record changed: 2017-07-02

Advertisement

Picture [LSUK] Life-Sciences-UK.com – The Business Web Portal 600x80px

More documents for Merus (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px